• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

ENBREL Indication Expanded

The FDA approved an expanded indication for Enbrel (etanercept) to inhibit the structural damage of active arthritis in patients with psoriatic arthritis, reported Amgen Inc. and Wyeth Pharmaceuticals.

Related Videos
Related Content
Multicenter Study Sheds Light on Pediatric MMP
April 3rd 2025

Multicenter Study Sheds Light on Pediatric MMP

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
August 1st 2023

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

Dupilumab Reduces Levels of Immunoglobulin E in Pediatric Patients with Moderate-to-Severe AD
March 12th 2025

Dupilumab Reduces Levels of Immunoglobulin E in Pediatric Patients with Moderate-to-Severe AD

The Cutaneous Connection
August 5th 2021

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

FDA Accepts Supplemental New Drug Application for Arcutis’ Roflumilast in Children with AD
February 26th 2025

FDA Accepts Supplemental New Drug Application for Arcutis’ Roflumilast in Children with AD

Reviewing Complex Cases: Topicals for Pediatric AD
February 25th 2025

Reviewing Complex Cases: Topicals for Pediatric AD

© 2025 MJH Life Sciences

All rights reserved.